Type 1 diabetes is a disease that progresses sequentially, at variable rates, through identifiable stages prior to the onset of symptoms to clinical diagnosis. The ability to identify at-risk presymptomatic individuals has provided a setting in which type 1 diabetes prevention can be contemplated, as well as an unprecedented opportunity to study the evolution of the disease. In this issue, Battaglia et al (DOI https://doi.org/10. 1007/s00125-017-4384-2) outline how Type 1 Diabetes TrialNet, an international consortium of clinical trial centres focused on intervention and prevention studies accompanied by deep longitudinal bio-sampling, is a key player in this area. The consortium's power lies in its ability to integrate clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnerships with industry. This has provided TrialNet with an enviable and unique working model in the field of translational medicine. The authors highlight the 'TrialNet model' of conducting wide-ranging studies ancillary to trials and signpost examples of important advances in our Competition for publication in Diabetologia continues to grow, and less than 20% of papers are accepted. Of all the high-quality papers that appear in this month's issue I want to draw your attention to five articles that I think are particularly interesting. The articles are summarised here. Our publisher, Springer, has kindly made the full text of each of these papers freely available. I hope you enjoy reading them! understanding of this disease, which could only be realised using this type of 'team science' approach. They conclude that this approach has pushed the field forward in multiple directions, and has begun to reveal biomarkers and deliver the mechanistic understanding necessary to combat type 1 diabetes.
The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study Lin Xu, Maria Carolina Borges, Gibran Hemani, Debbie A. Lawlor
As the average BMI is increasing globally, with a large number of people now obese and few effective and sustainable treatments (apart from bariatric surgery) for obesity, it is important to identify modifiable mediators of the impact of high BMI on disease outcomes. In this issue, Xu et al (DOI https://doi.org/10.1007/s00125-017-4396-y) sought to determine whether glycaemic/insulin and lipid traits were causal mediators of the effect of BMI on CHD. To test for mediation, the authors used Mendelian randomisation (MR), the use of genetic instruments to test causal effects, which is less prone to the biases of conventional multivariable regression. The MR results supported a positive effect of BMI on CHD risk that was mediated through triacylglycerols, HbA 1c and type 2 diabetes. These findings indicate the extent to which acting on these risk factors might counteract the detrimental effects of obesity on CHD, and highlight the potential importance of using interventions that address these risk factors, specifically in those who are obese.
Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion Felicia Gerst, Robert Wagner, Gabriele Kaiser, Madhura Panse, Martin Heni, Jürgen Machann, Malte N. Bongers, Tina Sartorius, Bence Sipos, Falko Fend, Christian Thiel, Silvio Nadalin, Alfred Königsrainer, Norbert Stefan, Andreas Fritsche, Hans-Ulrich Häring, Susanne Ullrich, Dorothea Siegel-Axel Obesity is associated with fatty liver and fatty pancreas. However, the role of pancreatic steatosis in the development of type 2 diabetes is not understood. In this issue, Gerst et al (DOI https://doi.org/10.1007/s00125-017-4385-1) report that pancreatic pre-adipocytes and adipocytes have a proinflammatory potential that can be induced by palmitate and fetuin-A, a hepatokine secreted from the fatty liver. In human pancreatic resections, increased immune cell infiltration was detected in islets located in the vicinity of adipocytes. Furthermore, in human islets, fetuin-A increased cytokine production by resident immune cells and inhibited glucoseinduced insulin secretion. The effect of fetuin-A on cytokine production was dependent on toll-like receptor 4 (TLR4), whereas the inhibition of insulin secretion occurred independently of TLR4. From these findings, Gerst and colleagues propose that a fetuin-A-mediated metabolic crosstalk between fatty liver and fatty pancreas exacerbates pancreatic inflammation and impairs insulin secretion, contributing to overt diabetes.
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